)
)
)
ImmuneOnco Biopharmaceuticals Inc. (HKSE:1541.HK)
March 02, 2026
Ballroom I C
Type: Company Presentation
Focus Area:
Oncology
ImmuneOnco is a Hong Kong-listed (Stock Code: HK.1541) clinical-stage biotechnology company dedicated to discovering and developing immunotherapies for the treatment of cancer and other diseases. Timdarpacept, a SIRPα-IgG1 Fc fusion protein, is currently in Phase III clinical development for the first-line treatment of chronic myelomonocytic leukemia (CMML), with a potential Biologics License Application (BLA) submission by the end of 2026. Amulirafuspalfa, a first-in-class CD47×CD20 bispecific antibody, is on the verge of initiating Phase III study. It is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma (end of Phase II) and systemic lupus erythematosus (SLE, Phase Ib). IMC-003 (an ActR2A-Fc fusion protein) — featuring enhanced affinity and potent blocking activity — is in Phase I for the treatment of pulmonary arterial hypertension (PAH). A trispecific candidate targeting GDF-9/ActR2A/ActR2B is currently in the preclinical stage.
Year Founded:
2015
Lead Product in Development:
Timdarpacept, a SIRPα-IgG1 Fc fusion protein, is currently in Phase III clinical development for the first-line treatment of chronic myelomonocytic leukemia (CMML), with a potential Biologics License Application (BLA) submission by the end of 2026.
Amulirafuspalfa, a first-in-class CD47×CD20 bispecific antibody, is on the verge of initiating Phase III study. It is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma (end of Phase II) and systemic lupus erythematosus (SLE, Phase Ib).
Speakers
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
